Prescription weight loss with GLP-1 drugs has moved decisively out of specialist clinics and into everyday medicine. In May 2026, the FDA approved orforglipron (Foundayo), Eli Lilly's once-daily oral GLP-1 receptor agonist, for chronic weight management — no fasting window required, no injection, easier to manufacture than its predecessors. That follows the WHO's December 2025 global guideline recognising obesity as a chronic, relapsing disease and formally positioning GLP-1 therapies as a standard component of its management. These are not niche developments. They signal a class of drugs that is becoming as routine as statins.
But the expanding availability of GLP-1s is also surfacing questions that go beyond whether they work for weight reduction. Emerging data on lean body mass loss, micronutrient depletion, and the limits of scale-based success metrics are reshaping how clinicians — particularly those practising functional and integrative medicine — think about what it actually means to get healthier on these drugs. If you are already taking a GLP-1, considering one, or simply trying to understand what the evidence says, those questions are worth understanding clearly.
The WHO's first dedicated guideline on GLP-1 obesity treatment is a landmark. It added GLP-1 therapies to its Essential Medicines List in September 2025 for managing type 2 diabetes in high-risk groups, and the December guideline goes further, framing obesity not as a lifestyle failure but as a chronic, complex disease requiring lifelong care. Medication, behavioural support, dietary change, and long-term follow-up are all part of that framework. No single element does the job alone.
What orforglipron adds to this picture is access. Previous injectable GLP-1s required cold-chain logistics and patient tolerance of injections. Oral semaglutide, approved by the FDA in December 2025, still demands a specific morning dosing window before food or liquid. Orforglipron has no such restrictions and, as a small molecule, is less complex to manufacture at scale. The practical barrier to starting prescription weight loss treatment has dropped substantially, and that will matter in markets like Hong Kong where private healthcare access is broad and demand for preventive metabolic health management is growing.
Here is the complication that mainstream coverage tends to understate. Weight loss on GLP-1s is real and well-documented, but not all weight is equal. A growing body of evidence suggests that a meaningful proportion of the weight lost on these drugs is lean body mass — muscle, bone, and connective tissue — rather than fat alone.
A large-scale analysis published on medRxiv in April 2026, drawing on over 670,000 first-episode GLP-1 users with paired body-composition measurements, found that tirzepatide was associated with greater relative lean body mass loss than semaglutide at every measured time point across the first year: excess lean mass losses of 1.1%, 1.5%, 1.3%, and 2.0% at three, six, nine, and twelve months respectively. The researchers also defined a "depletive GLP-1 metabotype" — total body weight loss above 20% combined with lean body mass loss above 5% — and found it significantly more common with tirzepatide than semaglutide (10.3% versus 6.7%). This is a preprint and has not yet completed peer review, but the sample size and methodology make it difficult to dismiss.
Why does this matter? Lean body mass is not cosmetic. Skeletal muscle is metabolically active tissue: it regulates insulin sensitivity, supports immune function, underpins physical capacity, and in older adults is one of the strongest predictors of long-term health outcomes. Losing it while the scale moves in a favourable direction is a trade-off that may not show up in standard weight-based assessments for months or years.
Alongside lean mass, there is a growing evidence base around micronutrient deficiencies in people taking GLP-1 drugs. These medications work in part by suppressing appetite and slowing gastric emptying — mechanisms that reduce how much you eat and, consequently, how much of key nutrients you absorb.
A 2026 narrative review published in Clinical Obesity, covering six studies involving 480,825 adults, found that GLP-1 receptor agonist use was associated with deficiencies in vitamin D, iron, and B vitamins. Vitamin D deficiency appeared in 7.5% of users at six months and 13.6% at twelve months. Iron depletion was substantial, with GLP-1 users showing 26–30% lower ferritin levels than comparator groups on SGLT2 inhibitors. More than 60% of users consumed below estimated requirements for calcium and iron. Thiamine and cobalamin (B1 and B12) deficits increased over time. Harvard Health's summary of the same review noted the researchers' conclusion that doctors should treat nutritional deficiency as a common consequence of GLP-1 therapy, not an occasional complication.
These are not abstract risks. Vitamin D and calcium insufficiency compound lean mass loss. Iron depletion causes fatigue and reduces exercise capacity. B12 deficiency affects neurological function. In the context of metabolic health optimisation, running these deficits quietly in the background undermines many of the benefits the drug is supposed to deliver.
This is where clinical framing diverges sharply from how GLP-1 outcomes are typically discussed in popular media. Scale weight is a proxy — a visible, easy-to-measure one, but a proxy nonetheless.
Dr. Tim Trodd, Functional Medicine Specialist at OT&P, addresses this directly. When asked what markers would concern him in someone appearing to do well on a GLP-1, he said: "Weight loss on its own tells me very little. I'd worry if the patient is losing strength, eating too little protein, feeling more fatigued, showing signs of micronutrient insufficiency, or seeing their waist shrink while their resilience, muscle mass, and overall function are quietly worsening. The real question is not whether they weigh less, but whether they're becoming harder to break, metabolically and physically."
That framing captures something the scale cannot. Being "metabolically smaller" — lighter but also weaker, more nutrient-depleted, and less physically robust — is a plausible outcome if a GLP-1 prescription runs without adequate dietary protein, micronutrient monitoring, or resistance training alongside it. The drug reduces appetite efficiently; it does not direct the body to preferentially lose fat rather than muscle, and it does not ensure nutritional adequacy when food intake drops substantially.
If you are taking a GLP-1 drug or weighing one up, a few areas are worth tracking beyond body weight:
None of this is an argument against GLP-1 drugs. The evidence for their effectiveness in reducing body weight and improving cardiometabolic risk markers is substantial, and the WHO's inclusion of them in its Essential Medicines List reflects that. The argument is for a broader set of outcomes to track alongside weight.
The arrival of accessible, oral prescription weight loss options places functional and integrative medicine practitioners in an interesting position. GLP-1s originated in diabetes management, migrated into obesity treatment, and are now entering general preventive health territory. Functional medicine has long emphasised root-cause metabolic assessment, body composition, dietary quality, and nutrient sufficiency — precisely the dimensions that scale-only GLP-1 monitoring misses.
The most coherent position for that discipline is neither reflexive resistance to pharmacology nor uncritical adoption. It is the kind of monitoring framework Dr. Trodd describes: tracking whether someone on a GLP-1 is becoming metabolically stronger or metabolically smaller, and intervening on the variables — protein, nutrients, resistance exercise, sleep — that the drug itself cannot address. That is where functional medicine standards add genuine value to a pharmaceutical tool that is otherwise being deployed with minimal metabolic oversight in many settings.
Anti-aging and longevity medicine communities have similar stakes in this question. Muscle mass, mitochondrial function, and micronutrient sufficiency are central concerns in both fields. GLP-1s can support fat loss and cardiometabolic markers; whether they support or erode the biological resilience that underlies long-term health depends entirely on how they are managed around the drug.
If you want to find a practitioner in Hong Kong who takes a metabolic rather than purely weight-focused view of GLP-1 therapy, you can search by specialisation and approach on Healwith.